NCT03885037Completed
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)
Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" General Investigation (Rheumatoid Arthritis)
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against rheumatoid arthritis under actual status of use.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 77 (actual)
- First submitted
- 4 Mar 2019
- Start date
- 20 Mar 2019
- Primary completion date
- 29 Nov 2024
- Lead sponsor
- Pfizer
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT03885037
What you commit to
- Study type: Observational
- Participants enrolled: 77
- From 20 Mar 2019 to the primary completion date, 29 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patients with rheumatoid arthritis who started treatment with this drug
- Patients who received this drug for the first time after the day of launch of this drug.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Local Country Office Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.